Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Co-occurring gain-of-function mutations in HER2 and HER3 modulate HER2/HER3 activation, oncogenesis, and HER2 inhibitor sensitivity
Ariella B. Hanker, Benjamin P. Brown, Jens Meiler, et al.
Cancer Cell (2021) Vol. 39, Iss. 8, pp. 1099-1114.e8
Open Access | Times Cited: 68

Showing 1-25 of 68 citing articles:

Targeting HER2-positive breast cancer: advances and future directions
Sandra M. Swain, Mythili Shastry, Erika Hamilton
Nature Reviews Drug Discovery (2022) Vol. 22, Iss. 2, pp. 101-126
Open Access | Times Cited: 562
A Comprehensive Review of HER2 in Cancer Biology and Therapeutics
Xiaoqing Cheng
Genes (2024) Vol. 15, Iss. 7, pp. 903-903
Open Access | Times Cited: 21
Structures of the HER2–HER3–NRG1β complex reveal a dynamic dimer interface
Devan Diwanji, Raphael Trenker, Tarjani Thaker, et al.
Nature (2021) Vol. 600, Iss. 7888, pp. 339-343
Open Access | Times Cited: 95
HER2 + breast cancers evade anti-HER2 therapy via a switch in driver pathway
Alison Smith, Emanuela Ferraro, Anton Safonov, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 69
The Phase II MutHER Study of Neratinib Alone and in Combination with Fulvestrant in HER2-Mutated, Non-amplified Metastatic Breast Cancer
X. Cynthia, Jingqin Luo, Rachel A. Freedman, et al.
Clinical Cancer Research (2022) Vol. 28, Iss. 7, pp. 1258-1267
Open Access | Times Cited: 52
Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial
Komal Jhaveri, L.D. Eli, Hans Wildiers, et al.
Annals of Oncology (2023) Vol. 34, Iss. 10, pp. 885-898
Open Access | Times Cited: 29
HER2/PI3K/AKT pathway in HER2-positive breast cancer: A review
Linghui Pan, Jinling Li, Qi Xu, et al.
Medicine (2024) Vol. 103, Iss. 24, pp. e38508-e38508
Open Access | Times Cited: 15
Genetic interactions reveal distinct biological and therapeutic implications in breast cancer
Cai-Jin Lin, Xi Jin, Ding Ma, et al.
Cancer Cell (2024) Vol. 42, Iss. 4, pp. 701-719.e12
Closed Access | Times Cited: 9
LINE-1 promotes tumorigenicity and exacerbates tumor progression via stimulating metabolism reprogramming in non-small cell lung cancer
Zeguo Sun, Rui Zhang, Xiao Zhang, et al.
Molecular Cancer (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 29
Self-Assembled Multivalent Aptamer Drug Conjugates: Enhanced Targeting and Cytotoxicity for HER2-Positive Gastric Cancer
Wenjuan Ma, Yuting Yang, Zhiqiang Liu, et al.
ACS Applied Materials & Interfaces (2023) Vol. 15, Iss. 37, pp. 43359-43373
Closed Access | Times Cited: 19
Breast Cancer Mutations HER2V777L and PIK3CAH1047R Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance
Xiaoqing Cheng, Yirui Sun, Maureen Highkin, et al.
Cancer Research (2023) Vol. 83, Iss. 17, pp. 2839-2857
Closed Access | Times Cited: 13
Acquired Secondary HER2 Mutations Enhance HER2/MAPK Signaling and Promote Resistance to HER2 Kinase Inhibition in Breast Cancer
Arnaldo Marín, Abdullah Al Mamun, Hima Patel, et al.
Cancer Research (2023) Vol. 83, Iss. 18, pp. 3145-3158
Closed Access | Times Cited: 13
Antibody–drug conjugates transform the outcome of individuals with low‐HER2‐expression advanced breast cancer
Fei Qu, Rongrong Lu, Qian Liu, et al.
Cancer (2024) Vol. 130, Iss. S8, pp. 1392-1402
Closed Access | Times Cited: 5
Trans-activating mutations of the pseudokinase ERBB3
Marika K.A. Koivu, Deepankar Chakroborty, Tomi T. Airenne, et al.
Oncogene (2024) Vol. 43, Iss. 29, pp. 2253-2265
Open Access | Times Cited: 5
Mechanisms of acquired resistance to HER2-Positive breast cancer therapies induced by HER3: A comprehensive review
Wujun Geng, H Thomas, Zhiyuan Chen, et al.
European Journal of Pharmacology (2024) Vol. 977, pp. 176725-176725
Open Access | Times Cited: 5
Allele-specific activation, enzyme kinetics, and inhibitor sensitivities of EGFR exon 19 deletion mutations in lung cancer
Benjamin P. Brown, Yunkai Zhang, Soyeon Kim, et al.
Proceedings of the National Academy of Sciences (2022) Vol. 119, Iss. 30
Open Access | Times Cited: 20
Expert Consensus on the Diagnosis and Treatment of NRG1/2 Gene Fusion Solid Tumors
C. Xu, Qian Wang, Dong Wang, et al.
Global Medical Genetics (2024) Vol. 11, Iss. 01, pp. 086-099
Open Access | Times Cited: 4
The Biological Roles and Clinical Applications of the PI3K/AKT Pathway in Targeted Therapy Resistance in HER2-Positive Breast Cancer: A Comprehensive Review
Hanyi Zhong, Ziling Zhou, Han Wang, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 24, pp. 13376-13376
Open Access | Times Cited: 4
Noninvasive identification of HER2 status by integrating multiparametric MRI-based radiomics model with the vesical imaging-reporting and data system (VI-RADS) score in bladder urothelial carcinoma
Cheng Luo, Shurong Li, Yichao Han, et al.
Abdominal Radiology (2025)
Closed Access
ERBB3-related gene PBX1 is associated with prognosis in patients with HER2-positive breast cancer
Shaobo Mo, Zhong Hai-ming, Wei-Ping Dai, et al.
BMC Genomic Data (2025) Vol. 26, Iss. 1
Open Access
Silver Jubilee of HER2 targeting: a clinical success in breast cancer
Jianli Zhao, Ziyue Zhou, Phei Er Saw, et al.
Journal of the National Cancer Center (2025)
Open Access
New Gain-of-Function Mutations Prioritize Mechanisms of HER2 Activation
Christopher J. Giacoletto, Liz J. Valente, Lancer Brown, et al.
medRxiv (Cold Spring Harbor Laboratory) (2025)
Open Access
Breast Cancer, HER2 Mutations, and Overcoming Drug Resistance
Ron Bose, X. Cynthia
New England Journal of Medicine (2021) Vol. 385, Iss. 13, pp. 1241-1243
Closed Access | Times Cited: 25
SIBP-03, a novel anti-HER3 antibody, exerts antitumor effects and synergizes with EGFR- and HER2-targeted drugs
Wenjing Li, Chengying Xie, Xi Zhu, et al.
Acta Pharmacologica Sinica (2024) Vol. 45, Iss. 4, pp. 857-866
Closed Access | Times Cited: 3
Elucidation of clinical implications Arising from circadian rhythm and insights into the tumor immune landscape in breast cancer
Chunjie Sun, Hanyun Zhang, Ye Li, et al.
Heliyon (2024) Vol. 10, Iss. 6, pp. e27356-e27356
Open Access | Times Cited: 3
Page 1 - Next Page

Scroll to top